Connect Biopharma Stock Plunges As Ulcerative Colitis Candidate Flunks In Mid-Stage Study


Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.


  • Connect Biopharma Holdings Limited (NASDAQ:CNTBannounced topline results at 12 weeks from its Phase 2 trial for CBP-307 (CBP-307CN002) for ulcerative colitis.
  • CBP-307 0.2 mg demonstrated a numerical reduction for the primary endpoint of least squares mean change from baseline in adapted Mayo Score at Week 12 that did not meet statistical significance. 
  • The Mayo Score (stool frequency, rectal bleeding, and endoscopy scores) at Week 12 for CBP-307 0.2 mg and placebo were -2.65 and -2.01, respectively (p=0.103). 
  • Read Next: Connect Biopharma's Mid-Stage Atopic Dermatitis Trial Meets Primary Endpoint.
  • A significantly higher proportion of patients reached clinical remission compared to placebo.
  • Additionally, reductions in lymphocyte counts amongst individuals receiving CBP-307 0.2 mg confirmed the pharmacodynamic activity of CBP-307 in patients with active UC.
  • Across the CBP-307 0.2 mg and placebo groups, occurrence of drug-related treatment-emergent adverse events were 66.0% and 38.5%, respectively. 
  • The company intends to engage in partnership discussions for the future development of CBP-307 to focus on the lead program CBP-201.
  • Price Action: CNTB shares traded 32.5% lower at $1.31 in pre-market on the last check Wednesday.

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefswhy it's moving